The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

BLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.

VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.

BLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Hemato is a pioneering open-access journal dedicated to the field of hematology, published by the esteemed MDPI from its base in Basel, Switzerland. Launched in 2020, this journal aims to provide a platform for researchers, clinicians, and professionals to share significant findings and advancements in blood-related disciplines over a converged timeframe until 2024. With a commitment to disseminating high-quality research, Hemato seeks to foster collaboration and innovation in hematological studies, showcasing original articles, reviews, and clinical studies that contribute to expanding knowledge in this vital area. As an open-access journal, it promotes accessible scholarship, ensuring that groundbreaking research reaches a broad audience, thereby enhancing the impact on the global health community.